JPM Interview: Lilly CEO Lechleiter On The Cost Of Innovation
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. is back on the path to growth with new products being added to its revenue mix, and CEO John Lechleiter wants to make sure that the company's and the biopharma industry's investments in research for new drugs are protected.